Page 33 - New epidemiological and PSMA-expression based paradigms in salivary gland tumors
P. 33
Table 1. continued
Side Left Right
Unknown
Treatment
Procedure Local excision
Partial parotidectomy
Total parotidectomy / Submandib. gl.resection
Subtotal parotidectomy Excision deep lobe parotid Biopsy
Unknown type of excision Missing
Negative
Positive Uncertain Unknown
Overall (n=3 506)
1 423 (41) 1 399 (40) 684 (19)
297 (8)
1 214 (35) 227 (6)
67 (2)
103 (3) 114 (3)
1 449 (41) 35 (1)
2 028 (58)
491 (14) 261 (7) 726 (21)
Primary (%)
Male (n=1 421)
571 (40) 560 (39) 290 (20)
Female (n=2 085)
852 (41) 839 (40) 394 (19)
1st Recurrence (%)
Overall (n=125)
64 (51) 53 (42) 8 (6)
2
Salivary gland pleomorphic adenoma in the Netherlands
Clear margins
Table 2a. Number of SGPAs in the cohort in relation to the Dutch population
SGPAs (n) Dutch population (n)
M F Total M F Total
1992
1997
2002
2007
2012
Total 1 421
343 596 384 664 401 689 466 770 491 787 2 085 3 506
7 480 422 7 696 803 7 971 967 8 088 514 8 282 871
7 648 728 7 870 304 8 133 318 8 269 478 8 447 477
15 129 150 15 567 107 16 105 285 16 357 992 16 730 348
per year)
Total 4.19 4.54 4.39 4.85 4.69
253 280 288 304 296
Abbreviations: SGPA salivary gland pleomorphic adenoma; M male; F female
Table 2b. Incidence of SGPAs in the Dutch population
Crude incidence (per 100 000 per ESR (per 100 000
year)
M F Total M F
1992 3.38 4.48 3.94 3.60 1997 3.64 4.88 4.27 3.91 2002 3.61 4.93 4.28 3.78 2007 3.76 5.64 4.71 3.88 2012 3.57 5.81 4.70 3.57
4.78 5.11 5.02 5.79 5.81
Abbreviations: ESR European Standardized Rate; SGPA Salivary Gland Pleomorphic Adenoma; M Male; F Female
31